Skip to main content
. 2010 Mar 19;160(1):36–47. doi: 10.1111/j.1476-5381.2009.00626.x

Figure 6.

Figure 6

Treatment of HaCaT cells with Ino-C2-platelet-activating factor (PAF) attenuates phosphorylation of the cytoplasmic tyrosine kinases FAK and Src. HaCaT cells maintained under sub-confluent conditions and treated with either 5 µM Ino-C2-PAF or under control conditions were labelled for pSrc (Y418) and pFAK (Y397).